Trial Profile
Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis (Liposomal Cisplatin Formulation) in Patients With Advanced or Refractory Tumours
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary)
- Indications Advanced breast cancer; Prostate cancer; Skin cancer; Solid tumours
- Focus Adverse reactions; Proof of concept
- Sponsors Allarity Therapeutics; LiPlasome Pharma; Oncology Venture
- 06 Jun 2023 Results (n=37) reporting efficacy and safety data from phase 2 portion of this trial in patients with mBC platinum naive presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 30 May 2023 Results presented in a CHOSA Oncology Media Release.
- 30 May 2023 According to Allarity Therapeutics media release, data from this study will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.